Liver transplantation is beneficial regardless of cirrhosis stage or acute-on-chronic liver failure grade: A single-center experience

doi:10.3748/wjg.v28.i40.5881

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4929)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

209

WORD

HTML

1869

Figures (1-2)

364

Tables (1-5)

324

Sum=2807

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

234

Download

446

Sum=680

Publishing Process of This Article

Item

Count

Browse

345

Download

1097

Sum=1442

Oct 28, 2022 (publication date) through Nov 16, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Oct 28, 2022; 28(40): 5881-5892
Published online Oct 28, 2022. doi: 10.3748/wjg.v28.i40.5881

Table 1 Patient characteristics (n = 235)

	CC, n = 11 (4.5%)	DC, n= 129 (52.9%)	ACLF, n = 95 (38.9%)	P value
Male gender, n (%)	6 (54.5)	64 (49.6)	47 (49.5)	0.95
Age, yr	57.0 (53.0-59.0)^a	52.0 (43.0-61.0)^c	50.0 (37.0-59.0)^a^,^c	0.02
Liver cirrhosis etiology, n (%)
Autoimmune	1 (9.1)^a	36 (27.9)^c	42 (44.2)^a^,^c	< 0.01
HCV	8 (72.7)^a^,^b	42 (32.6)^b^,^c	13 (13.7)^a^,^c	< 0.0001
Alcoholic liver disease	1 (9.1)	11 (8.5)	9 (9.5)	0.93
NASH	0 (0.0)	7 (5.4)	6 (6.3)	0.88
Cryptogenic	1 (9.1)	22 (17.1)	18 (18.9)	0.76
Other¹	0 (0.0)	11 (8.5)	7 (7.4)	0.84
Comorbidities, n (%)
Type 2 diabetes mellitus	3 (27.3)	22 (17.1)	13 (13.7)	0.44
Primary hypertension	2 (18.2)	20 (15.5)	6 (6.3)	0.06
Pre-transplant clinical data
MELD-Na	11 ± 3^a^,^b	19 ± 4^b^,^c	25 ± 6^a^,^c	< 0.0001
Total bilirubin (mg/dL)	1.18 (1.03-1.45)^a^,^b	3.39 (2.3-5.46)^b^,^c	7.70 (4.14-16.63)^a^,^c	< 0.0001
INR	1.1 (1.1-1.2)^a^,^b	1.5 (1.3-1.7)^b	1.5 (1.3-2.0)^a	< 0.0001
Serum creatinine (mg/dL)	0.67 (0.57-0.71)^a	0.73 (0.61-0.88)^c	0.97 (0.75-1.35)^a^,^c	< 0.0001
Leukocyte count (× 10⁹/L)	2.9 (2.4-3)^a	4 (3.1-5)^c	5.4 (3.8-6.8)^a^,^c	< 0.0001
Disease manifestations², n (%)
Clinical ascites	0 (0.0)^a^,^b	88 (68.2)^b^,^c	88 (92.6)^a^,^c	< 0.0001
Encephalopathy	0 (0.0)^a^,^b	69 (53.5)^b^,^c	80 (84.2)^a^,^c	< 0.0001
Grade 3-4 encephalopathy (West- Haven)	0 (0.0)^a^,^b	7 (5.4)^b^,^c	37 (38.9)^a^,^c	< 0.0001

¹Includes secondary biliary cirrhosis, drug-induced liver injury, and congenital liver diseases.

²Disease manifestations during the whole clinical course until liver transplantation.

Comparisons between groups are shown with superscript letters.

^aSignificant difference between CC and ACLF.

^bSignificant difference between CC and DC.

^cSignificant difference between DC and ACLF.

ACLF: Acute-on-chronic liver failure; CC: Compensated cirrhosis; DC: Decompensated cirrhosis; HCV: Hepatitis C virus; INR: International normalized ratio; MELD Na: Model for End-Stage Liver Disease-Sodium; NASH: Non-alcoholic steatohepatitis.

Citation: Cervantes-Alvarez E, Vilatoba M, Limon-de la Rosa N, Mendez-Guerrero O, Kershenobich D, Torre A, Navarro-Alvarez N. Liver transplantation is beneficial regardless of cirrhosis stage or acute-on-chronic liver failure grade: A single-center experience. World J Gastroenterol 2022; 28(40): 5881-5892
URL: https://www.wjgnet.com/1007-9327/full/v28/i40/5881.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i40.5881